Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you have Crohn's disease and are considering semaglutide for weight management, the short answer is that there is no blanket prohibition — but the decision depends heavily on your individual disease history, current activity, and what medications you are already taking. Semaglutide is a prescription-only medicine; a prescriber, not a checklist, has to weigh the specifics of your gut condition before any treatment starts. Wegovy (the weight-management brand of semaglutide) slows gastric emptying and reduces appetite via the GLP-1 pathway, and those same mechanisms are the reason the conversation with a clinician matters more than usual here.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide activates GLP-1 receptors in the gut wall and the brain. In practical terms, that means the stomach empties more slowly and hunger signals quieten down. For most people, those effects are straightforwardly useful. For someone living with Crohn's disease, they carry more nuance.
Slowed gastric emptying can alter transit time through the bowel, and that matters when the bowel is already inflamed or has areas of narrowing. There is also the question of symptom overlap: nausea, cramping, changes in stool frequency and loose stools are well-documented side effects of semaglutide during the early weeks of treatment, and they are, of course, also classic Crohn's symptoms. A prescriber reviewing your case will think about how that overlap could complicate day-to-day monitoring of your IBD. That's not a reason to rule anything out; it is a reason to plan carefully from the start. The full clinical profile of semaglutide covers those early GI effects in more detail.
Worth adding: research into GLP-1 receptor agonists and inflammatory bowel conditions is still at an early stage. A question our prescribers hear most weeks is whether semaglutide could actually help inflammation in the gut, and there is also a related conversation worth having about how semaglutide can interact with other aspects of health beyond the gut, some pre-clinical data are intriguing, but there are no controlled trials in people with Crohn's disease yet, and no licensed indication in that direction. The NHS patient page on semaglutide's side effects and interactions gives a grounded starting point.
People managing Crohn's disease often take long-term medication: mesalazine, azathioprine, mercaptopurine, methotrexate, or newer biologics. Most of those are given by injection or infusion, so semaglutide's effect on gastric emptying is not a direct concern for them. The situation is more complicated if you are taking an oral immunosuppressant or a corticosteroid by mouth.
Oral medicines that depend on consistent gut absorption (and on being absorbed at a particular point in the digestive tract) can behave differently when transit time changes. This is a particular concern highlighted for oral contraceptives taken alongside tirzepatide, and the principle extends to other oral medicines. If any of your Crohn's medications are oral, tell your prescriber the full list before starting semaglutide; they may want to coordinate with your gastroenterologist.
Biologics such as adalimumab, infliximab or vedolizumab are given by injection or infusion, so their absorption is not affected by semaglutide. That is a reassuring fact for a significant proportion of people with moderate-to-severe Crohn's disease. If you are curious about cost context for weight-loss treatment more broadly, this page on Wegovy pricing in the UK explains what a private prescription normally includes. The semaglutide dosing and titration guide is also worth reading before any consultation.
Active Crohn's flares and elective weight-management treatment rarely sit well together. When the gut is inflamed, adding a medicine that independently causes nausea and loose stools raises the risk of significant discomfort, dehydration, and difficulty telling what is a side effect and what is the disease worsening. Most clinicians would want your IBD to be in stable remission, ideally confirmed by your gastroenterologist, before starting semaglutide.
That said, stable, well-controlled Crohn's disease is not the same as severe active disease. Many people with Crohn's live long stretches in remission and carry a BMI that puts them at meaningful risk of cardiovascular disease or type 2 diabetes, exactly the conditions where semaglutide's benefits are well established. NICE's appraisal of semaglutide for weight management, TA875, sets out the eligibility criteria; it does not exclude IBD patients, but it requires treatment within a specialist service with multidisciplinary oversight, which is the right frame for someone with a complex gut history anyway.
The practical path forward: get your gastroenterologist's view on your current disease status, bring that summary to your weight-management prescriber, and ask about a shared-care plan that flags what would prompt a pause. Our Wegovy treatment overview outlines how the private prescription route works for people who meet the clinical criteria. You can also explore the range of weight-loss treatment options if you want to see the wider picture before committing to a conversation.
At nume (sorry, at a regulated online pharmacy like ours) a GPhC-registered Independent Prescriber reviews your medical history personally, not via automated filtering. For someone with Crohn's disease, that review will typically ask about current disease status, recent flares, any bowel surgery (resections, strictures, stomas), current medications, and nutritional status. Malnutrition is not uncommon in active Crohn's disease, and significant calorie restriction on top of semaglutide's appetite suppression is something a prescriber needs to factor in.
Bowel resections deserve a specific mention. If you have had part of your small intestine removed, drug absorption can be altered even at baseline. Semaglutide's injectable form bypasses the gut for absorption (it is given subcutaneously) so the drug itself gets in regardless. But if you are on any oral medicines for other conditions, those warrant closer scrutiny post-resection.
People with a stoma should tell their prescriber: output changes during early semaglutide treatment are common, and a prescriber who knows about a stoma can advise on what changes to watch for and when to seek help. The NHS advises reporting unexpected or severe side effects via the MHRA Yellow Card scheme, which is open to patients and carers. If this page has raised questions specific to your situation, our team is available seven days a week, and starting a free consultation is straightforward when you are ready.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.